Literature DB >> 25394989

Renal denervation in the treatment of resistant arterial hypertension.

Thomas Lambert1, Wilhelm Schützenberger, Clemens Steinwender.   

Abstract

Patients with resistant arterial hypertension have an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. In many cases, limitations of pharmacological treatment like intolerance and adherence to the antihypertensive medications are present in the clinical setting. In this context, new treatment options like trans-femoral sympathetic renal nerve denervation is, even after publication of the Symplicity HTN-3 trial, a promising new treatment option.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25394989     DOI： 10.1007/s10354-014-0330-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  37 in total

1.  Renal denervation in moderate to severe CKD.

Authors:  Dagmara Hering; Felix Mahfoud; Antony S Walton; Henry Krum; Gavin W Lambert; Elisabeth A Lambert; Paul A Sobotka; Michael Böhm; Bodo Cremers; Murray D Esler; Markus P Schlaich
Journal:  J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 10.121

Review 2.  Renal denervation for hypertension.

Authors:  Stefan C Bertog; Paul A Sobotka; Horst Sievert
Journal:  JACC Cardiovasc Interv       Date:  2012-03       Impact factor: 11.195

Review 3.  Renal denervation for hypertension.

Authors:  Mackram F Eleid; Gary L Schwartz; Rajiv Gulati
Journal:  Curr Probl Cardiol       Date:  2013-11-11       Impact factor: 5.200

4.  Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans.

Authors:  Zachary A Marcum; Megan E Amuan; Joseph T Hanlon; Sherrie L Aspinall; Steven M Handler; Christine M Ruby; Mary Jo V Pugh
Journal:  J Am Geriatr Soc       Date:  2011-12-08       Impact factor: 5.562

5.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 7.  Response and non-response to renal denervation: who is the ideal candidate?

Authors:  Christian Ukena; Bodo Cremers; Sebastian Ewen; Michael Böhm; Felix Mahfoud
Journal:  EuroIntervention       Date:  2013-05       Impact factor: 6.534

8.  Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.

Authors:  Giampiero Mazzaglia; Ettore Ambrosioni; Marianna Alacqua; Alessandro Filippi; Emiliano Sessa; Vincenzo Immordino; Claudio Borghi; Ovidio Brignoli; Achille P Caputi; Claudio Cricelli; Lorenzo G Mantovani
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.